Taiwan flags local Clade Ib mpox as Congo Ebola and U.S. Cyclospora pressures grow
Today’s health agenda spans infectious-disease surveillance, food safety, oncology and medical-technology resilience. Taiwan confirmed its first local Clade Ib mpox cases while schools prepare for respiratory-virus pressure; WHO warned Asia-Pacific systems to stay ready for H5N1; Ebola remains uncontrolled in Congo; the United States is tracking a large Cyclospora season; and FDA approved a first-in-class targeted pancreatic-cancer drug.
Taiwan reports its first local Clade Ib mpox cases as schools prepare for respiratory-virus season
Taiwan CDC reported two locally acquired Clade Ib mpox cases in August, both men in their 30s who had not received mpox vaccine before illness. They are Taiwan’s first local Clade Ib cases, bringing the country’s 2026 mpox total to 28 cases through August 23, including 19 local and 9 imported cases; since mpox became a notifiable disease in 2022, Taiwan has recorded 544 cases. CDC said Clade Ib and Clade II can both cause fever, swollen lymph nodes and rash or pustules, but Clade Ib may have wider rash distribution and greater household-transmission risk. The warning lands as schools reopen: in week 33, Taiwan recorded 24,995 COVID-19 outpatient and emergency visits, 94,340 influenza-like illness visits, 6,546 enterovirus visits and 134 dengue cases so far this year, putting clinics and school prevention routines under renewed pressure.
Read the full story
WHO warns Asia-Pacific not to let H5N1 surveillance lag
WHO’s South-East Asia and Western Pacific offices used a three-day regional influenza meeting ending August 27 to put highly pathogenic avian influenza A(H5N1) at the center of preparedness planning. More than 150 influenza experts, laboratory scientists and public-health officials reviewed how surveillance data can move faster into public-health decisions, including for H5N1 outbreaks in animals with possible spillover to humans. The meeting emphasized One Health coordination across animal, human and environmental authorities, with case studies from Australia, New Zealand, Bangladesh, India and other countries. The practical message is not that a human pandemic is underway, but that genomic sequencing, laboratory access, joint investigations and rapid risk assessment need to be ready before spillover events become hard to contain.
Read the full storyUganda’s Ebola outbreak is cleared, but Congo’s Bundibugyo epidemic remains uncontrolled
Reuters reported that WHO now considers Uganda’s Bundibugyo Ebola outbreak over after monitoring found no missed transmission chains, following Uganda’s July 28 declaration that the country was free of the disease; Uganda had recorded 20 cases and two deaths. The regional risk, however, has shifted rather than disappeared. WHO’s emergency-committee recommendations for the Democratic Republic of the Congo still classify the national risk as very high, and Reuters cited Congolese government figures of more than 5,600 cases and more than 2,700 deaths as of Tuesday. WHO officials said transmission remains very active, although contact tracing and testing have improved, and flagged a $30 million immediate logistics funding gap for medical supplies and protective equipment. Taiwan CDC has already extended border measures for the DRC to November 28, while planning to lift Uganda-related measures from August 28 if no new cases appear by August 27.
Read the full storyU.S. Cyclospora season reaches 17,180 confirmed domestic cases
CDC’s national surveillance page, updated August 25 with data through August 24, reports 17,180 laboratory-confirmed domestically acquired cyclosporiasis cases in the United States since May 1, compared with 1,180 cases reported during the May-to-August 2025 season. CDC says the true number is likely higher because some patients recover without testing and recent illnesses can take about six weeks to appear in federal data. The largest defined cluster remains the multistate outbreak linked to processed iceberg lettuce from central Mexico and Taylor Farms de Mexico: CDC lists 10,930 cases, 454 hospitalizations and two deaths across 17 states, while FDA says recalled lettuce should no longer be on the market but the investigation remains open. For clinicians, the key point is diagnostic: routine stool testing may not include Cyclospora, so persistent watery diarrhea after produce exposure may need specific testing and treatment.
Read the full storyFDA approves first-in-class RAS inhibitor for metastatic pancreatic adenocarcinoma
FDA approved Rasonque, or daraxonrasib, for adults with metastatic pancreatic adenocarcinoma who previously received at least one systemic therapy or are not candidates for multiagent systemic therapy. The once-daily tablet targets the RAS GTPase protein family, a key driver in many pancreatic adenocarcinomas; FDA says about 90% to 95% of the roughly 67,000 new U.S. pancreatic-cancer cases each year are adenocarcinoma. In the 500-patient RASolute 302 trial, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with physician’s-choice standard chemotherapy, with statistically significant improvements in progression-free survival and response rate. The approval came about 6.5 months before the FDA goal date and gives a hard-to-treat cancer a new targeted option, while adverse-event monitoring will focus on rash, diarrhea, stomatitis, gastrointestinal perforation, pneumonitis and embryo-fetal toxicity.
Read the full story
Boston Scientific cyber incident links hospital supply chains to medical-device security
Boston Scientific said it identified a cybersecurity incident on August 25 affecting certain IT systems, causing a network outage and disruption to operations. The company said access to some operating systems and business applications was affected, including systems used to process and ship customer orders; it activated incident-response protocols, brought in third-party cybersecurity experts and said the restoration timeline and full impact were still unknown. No public statement confirmed a specific threat actor, patient-data theft or direct patient harm. Still, for health systems, the episode is a reminder that medical-device security is not only about implant or bedside-device software: order-processing, shipping and enterprise systems can also become clinical-continuity risks when device supply chains are disrupted.
Read the full story
TPulled the most relevant stories from the last 24h — headlines, key points and original sources are all in.
JGot it. Wrote it up in four languages across six sections, leading with why this matters right now.
WFact-checked. Asked Jasper to tighten two figures and drop the AI-speak; the rest holds — ship it.
Explore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNews